Organic Active Ingredients TRIZ Cases

A 15%–30% moisture range helps all-white snus portions resist discoloration while preserving moistness, sensory characteristics, and controlled active-agent release.

Specific tricyclic molecular structures provide a route to inhibit mutant KRAS where effective treatment options remain limited.

Protected allylic alcohols reduce impurities in MCL-1 inhibitor synthesis, enabling cleaner scale-up without chromatography.

Charged polyester copolymers form polyplexes with biologics to improve delivery efficiency while reducing cytotoxicity and inflammatory response.

Thyroid hormone receptor beta agonists activate ABCD2 and VLCFA beta-oxidation to address X-ALD treatment limitations.

Dose reductions, blood-count monitoring, and G-CSF support help manage lurbinectedin-related hematological toxicity during SCLC treatment.

Pyrazolopyrimidine compounds target ALK2 and FGFR activity, expanding treatment options for cancer and anemia of chronic disease.

HDAC3 antagonists alter CD8+ T-cell epigenetic regulation to restore effector function and counter tumor-driven inactivation.

High-viscosity polymer in the capsule shell keeps trace amounts of tyndalized bacteria homogeneous and limits separation and sedimentation.

Cell-penetrating anti-DNA antibodies transport donor oligonucleotides into cells, increasing targeted editing frequency without nucleases or PNAs.

A dual-fluid irrigant mixes zinc or silver ions with chlorite at use to raise wound oxidation-reduction potential and sustain antimicrobial protection.

Real-time PCR targets IS481, IS1001, and hIS1001 to distinguish three Bordetella species and support faster treatment selection.

See how a formula (I) compound combined with lung surfactant targets inflammation and macrophage activity to address BPD and BPD-PH.

Oxidation can convert calcium channel-blocking 1,4-dihydropyridines into less active, more toxic pyridine analogues; chelating agents limit this degradation.

Taste-masking agents and suspending excipients create a palatable, homogeneous tasimelteon liquid for pediatric dosing.

Complementary oligonucleotides target LRRK2 RNA to reduce protein expression and address symptoms across Parkinson’s disease subtypes.

Cooling tissue before, during, and after capsaicin administration helps reduce transient burning while supporting extended joint pain relief.

Using template RNA, reverse transcriptase enables longer genetic sequence insertion into target cells while reducing DNA damage and interferon activation.

Controlled liquid-water hydration addresses cyclophosphamide moisture variability after freeze-drying, supporting storage stability and redissolving performance.

Aqueous dipeptide derivatives degrade enzymatically and resist sterilization; antioxidants, pH control, and lyophilization improve stability.

Varying molecular-weight polyglutamic acid compounds penetrate vaginal tissue layers to moisturize dryness without hormonal therapy.

Compound 1 targets TAAR1 and 5HT1A instead of D2 receptors to treat schizophrenia while reducing adverse events.

Selective pyrimidine ligands address poor A2A/A2B subtype selectivity while modulating immune responses in cancer and inflammatory disease.

A mixture of HCl and EDTANa4 helps stabilize LABA and corticosteroid pMDI formulations stored in aluminum cans.

Imidazolium-based cationic lipids in composite LNPs improve mRNA biodistribution and transfection for lung and spleen delivery.

Combination chemotherapy can raise normal-tissue toxicity; 5–50 nm EPR carriers concentrate conjugated drugs in tumors for controlled release.

Tertiary amine N-oxide lipids enable transcellular transport in liposomes, improving drug accumulation and penetration in target tissues.

Selective DHCR24 compounds address toxicity and specificity limits by increasing desmosterol for oral treatment of DHCR24-mediated disorders.

Electrospun PLGA and collagen scaffolds preload CHIR99021 to limit adipocyte infiltration and support muscle repair at the myotendinous junction.

Swelling, shaping, and adhesive materials control pirfenidone release for 24 hours, lowering peak-to-valley fluctuation for once-daily dosing.

Indazole compounds address T790M, L858R, and C797S EGFR resistance through selective inhibition of drug-resistant mutant kinases.

Aripiprazole raises NOXA and PUMA expression and promotes PARP cleavage to strengthen RAF inhibitor-induced cancer cell apoptosis.

GSTZ1 inhibitors block a resistance mediator and sensitize drug-refractory NSCLC cells to infigratinib or dasatinib.

Phosphorylated dihydroceramides modulate ceramidase activity to suppress oral cancer cells while sparing healthy tissue.

Formula (I) compounds preferentially inhibit persistent sodium current to reduce seizures while limiting toxicity linked to peak-current blockade.

Non-ionic surfactants and ester co-surfactants protect hydrolytically labile antipsychotics, limiting hydrolysis products below 50 ppm after 24 months.

An rAAV dose range of 5×10^13 to 1×10^15 genome copies/kg targets microdystrophin expression while managing immune-response risk.

Fisetin and quercetin elevate mitochondrial calcium to support chondrocyte function and help prevent cartilage degeneration.

An enteric core-shell tablet resists stomach acid, then disintegrates at intestinal pH for controlled delivery to targeted colon segments.

An HPMC-based ruxolitinib matrix maintains therapeutic plasma levels for up to 24 hours, reducing dosing frequency and harmful drug spikes.

Modular reaction steps and salt formation address AG-10 manufacturing limits while supporting yield, stability, and bioavailability.

Limited EPA/DHA protection against sea lice is addressed with a fish-diet supplement combining 22–30 wt.% Omega 3 and 8–20 wt.% Omega 7.

RALA peptide nanoparticles deliver coronavirus mRNA intracellularly while improving stability and supporting lyophilized vaccine storage.

RNAi constructs silence SCAP mRNA to reduce lipid synthesis and liver fat accumulation, addressing limited pharmacologic options for NAFLD.

Targeting ligands guide synthetic-backbone oligonucleotides toward selected cells, helping modulate genes while limiting off-target effects.

Combining ketamine and buprenorphine in a sublingual lozenge is presented as a way to accelerate treatment for opioid and alcohol addiction.

Intranasal delivery addresses oral metoclopramide's symptom burden in diabetic gastroparesis and lowers visits and hospitalizations.

Current arthritis treatments lack targeted ADAMTS inhibition; imidazolidine derivatives protect cartilage by inhibiting ADAMTS4 and ADAMTS5.

Existing treatments for DUX4 misexpression are ineffective; 2-aryl thiazole and benzothiazole compounds offer a new inhibition approach.

Lipid nanoparticles deliver EBV RNA antigens to address weak conventional vaccine responses and build neutralizing antibodies plus T-cell immunity.

Posaconazole derivatives eliminate renal toxicity risks from beta-cyclodextrin while maintaining antifungal efficacy.

Thraustochytrium fermentation yields docosapentaenoic acid-rich oil, resolving the cost bottleneck of enriching infant formulas with essential fatty acids.

A breast cancer classification system categorizes tumors using estrogen receptor, androgen receptor, and vitamin D receptor expression levels.

Aminopyrimidine compounds inhibit T790M mutant EGFR while sparing wild-type receptors, reducing toxic side effects in non-small cell lung cancer treatment.

Substituted pyrazolo-pyrazines modulate GluN2B receptor activity, addressing limited therapeutic options for depression and anxiety.

Extended release tablet formulation minimizes dissociative symptoms while maintaining rapid antidepressant onset for treatment-resistant depression.

Removing hazardous methyl iodide and boron tribromide from the synthetic pathway to enable commercially viable manufacturing of thyroid-like compounds.

A silylated polysaccharide hydrogel forms Si-O-Si bonds via sol-gel condensation.

NLRP3 inhibitors suppress PMN-MDSC tumor infiltration to augment anti-PD-1 antibody immunotherapy efficacy.

MicroRNA-200b administration reduces diabetic ulcer area by regulating angiogenesis and inflammation pathways.

Atovaquone derivatives inhibit STAT3 and mTOR signaling to suppress cancer cell growth while minimizing toxicity to normal tissues.

Segmented particle sizes direct naloxone to turbinates, avoiding lung deposition and systemic distribution for safer opioid overdose reversal.

Formula I compound inhibits FGFR4 kinase activity with high selectivity, reducing side effects from non-specific inhibition.

A nitrogen-containing tetracyclic compound binds covalently to the KRAS G12C mutant protein.

Deuterium substitution extends action time and reduces adverse reactions in dehydrophenylahistin antitumor drugs by slowing metabolic degradation.

Replacing benzalkonium chloride with EDTA and xanthan gum prevents oxidative degradation while maintaining therapeutic efficacy.

Formula I proline derivatives inhibit Cathepsin S and L, reducing extracellular matrix degradation to stabilize atherosclerotic plaques.

Mobile health application qualifies patients for over-the-counter dihydropyridine calcium channel blockers using automated electronic surveys.

Amorphous gallium complex formulation with enteric coating overcomes poor aqueous solubility to achieve plasma Cmax 100 times higher than crystalline forms.

Hybrid polymers combine cellulose ether and lactam moieties to solubilize poorly water-soluble drugs in pharmaceutical formulations.

Treprostinil erbumine salt eliminates rigid environmental controls by resisting moisture absorption and thermal degradation.

Substituted pyrazolo-quinazolines target MPS1 kinase to treat cancer while minimizing peripheral neuropathy and other toxic side effects.

Cationic bolaamphiphile complexes deliver nucleic acids to modify bacterial gene expression.

Alkaline ionized water spray decomposes uric acid tophus deposits through chemical neutralization.

Polyglycerol fatty acid ester composition maintains shape stability during 3D printing while accommodating active substances without brittleness.

Functional nucleic acid molecules enhance translation of endogenous mRNA sequences to treat nervous system disorders without exceeding physiological limits.

Non-viral chemically modified RNA delivery eliminates viral immunogenicity while sustaining BMP-2 secretion for effective bone healing.

Formula I compound inhibits TrkA signaling to treat acute and chronic pain without opioid addiction risks.

A heterocyclic amide compound inhibits RIP1 kinase activity to block programmed cell necrosis.

Rebamipide reduces intestinal permeability by restoring tight junctions, enabling corticosteroid dose reduction while maintaining inflammation control.

Differentiated guide and passenger strand complementarity in artificial microRNA constructs reduces off-target effects while maintaining high specificity.

Fluoroalkyl substitutions on benzodiazepinone cores resolve the trade-off between antitumor efficacy and metabolic stability.

Novel heterocyclic compounds inhibit IDO and TDO enzymes, restoring immune function by blocking tumor-promoting metabolic pathways.

Zinc phosphate complexes with stannous ions to prevent hydrolytic and oxidative losses, maintaining antimicrobial efficacy.

Combining an antipsychotic drug with a VMAT2 inhibitor reduces tardive dyskinesia risk while maintaining efficacy via synergistic action.

Localized active substance placement in cellulose fibre surfaces prevents skin drying and itching while maintaining mechanical strength and abrasion resistance.

A synthesis process for enantiomerically pure PDE10 inhibitors using chiral auxiliaries to establish stereochemistry early in the reaction sequence.

A noninvasive peripheral nerve stimulation system delivers electrical signals to limb nerves.

Specific compounds displace unstable water molecules in the TYK2 binding pocket, enhancing binding affinity and therapeutic efficacy for autoimmune disorders.

Peptides activate the Akt pathway to treat neurodegenerative diseases, using pAkt levels to monitor progression.

Trans-1,3-dilinolein selectively kills gastric cancer cells under hypoxic conditions without damaging normal gastric mucosal epithelial cells.

Purified bovine milk oligosaccharides incorporate fucose and sialic acid moieties to mimic human milk structures.

Targeted immunomodulatory antibodies bind suppressive molecules like TGF-beta to counteract tumor-induced immune tolerance and enhance chemotherapy efficacy.

Cross-linked chitosan and dextran polymers form a hydrogel barrier that prevents fibrin adhesion.

Wet-milled superdisintegrant composite particles break up nanoparticle aggregates to enhance drug recovery and dissolution rates.

Topical TRPA1 inhibitors reduce UVB-induced skin inflammation and pain by selectively constraining TRPV4 and TRPA1 channels.

Prodrug-linked nucleoside derivatives improve bioavailability and disease-free survival rates in liver cancer and leukemia treatments.

Form T3 and Form T4 of Ponesimod improve bioavailability and handling by resolving formulation difficulties inherent in existing solid state structures.

1,3,4-Oxadiazole compounds inhibit superoxide dismutase expression through targeted kinase modulation.

A PEG-modified cationic liposome binds shRNA via electrostatic interaction to enhance cancer cell targetability.

Heteroaryl-substituted pyridines resolve metabolic instability contradictions while maintaining antifungal efficacy against resistant pathogens.

Small molecule inhibitors overcome large biologic limitations by targeting MASP-2 to treat complement-associated diseases.

Pyrimidinone compounds inhibit 17β-HSD13 to reduce liver damage and pulmonary fibrosis progression.

Optimizing the weight ratio of collagen hydrolysate to fucoidan facilitates collagen transport, reducing joint friction and pain during movement.

A dietary composition combining mulberry, green coffee, and white bean extracts to regulate blood glucose levels.

A CD8 vaccine targeting HIV antigens paired with interferon alpha blocking agents to potentiate immune responses.

Stable apomorphine pharmaceutical composition using pH control and inert packaging for injectable devices.

A quercetin-3 β-O-D-glucoside kit inhibits viral entry for Ebola and Zika protection.

Replacing the alpha-beta unsaturated ketone fragment in existing dual agonists with a triazolone core improves metabolic stability and clinical effectiveness.

Isolate active HBV RNAseH using nickel-agarose affinity chromatography to screen inhibitors that suppress viral replication beyond cccDNA persistence limits.

Enzymatic linker cleavage releases cytotoxic pyrrolobenzodiazepine dimers at tumor sites, reducing toxicity to normal cells.

Lipid encapsulated dsRNA suppresses complement C5 expression, replacing costly monoclonal antibodies with affordable nucleic acid therapy.

Nicotinic acid N-oxide derivatives inhibit the enzyme 3-hydroxyanthranilate-3,4-dioxygenase through competitive binding to the catalytic Fe2+ ion.

Rebamipide promotes glycocalyx secretion to restore the vascular endothelial barrier and improve arterial elasticity.

Carbamylated albumin fraction predicts mortality risk by replacing unreliable blood urea nitrogen markers with specific antibody detection.

Engineered U7 snRNAs incorporate smOPT and kiss domains to direct precise exon skipping or inclusion in muscle cells.

A biodegradable ophthalmic implant matrix slowly releases active pharmaceutical ingredients into the vitreous humor.

Hypoxic environments and antioxidants prevent oxidative stress, preserving hematopoietic stem cells for transplantation.

Novel Sitagliptin salt crystals enhance pharmaceutical properties through specific solid-state structures.

Pro-resolving lipid mediators attenuate inflammatory responses and reduce neointimal hyperplasia to prevent restenosis.

Aqueous plasma protein-bound cannabinoid compositions enable rapid absorption of active ingredients through standard extraction and formulation processes.

Formula II compounds inhibit ERK1/2 to overcome resistance in patients previously treated with BRAF or MEK inhibitors.

A pharmaceutical composition containing GRIM19 protein inhibits hepatitis C virus replication through targeted cellular modulation.

Specific angiotensin II receptor antagonists improve therapeutic effectiveness for bone metabolic diseases by blocking osteoclast activity.

Early asymmetric transamination eliminates chiral resolution waste and chromatography for scalable Savolitinib manufacturing.

A modular inhaler uses a removable cartridge and wick assembly to vaporize liquid formulations via an atomizer.

Topical Coenzyme Q10 treats skin cancer by exploiting the Warburg effect to selectively kill malignant cells while sparing healthy tissue.

Block copolymer carriers encapsulate hydrophobic cyclopeptides, resolving solubility limits while blocking protective autophagy pathways.

Measuring succinyl-CoA levels in cardiomyocytes and mitochondrial complex II respiratory capacity in peripheral blood mononuclear cells.

Modified double-stranded DNA triggers STING signaling to activate immune cells while avoiding chronic autoinflammatory disease from self-DNA detection.

A selective imidazopyrazine compound targets the PI3Kδ enzyme to inhibit its activity.

A lipoic acid and vitamin D composition treats neurodegenerative diseases by synergistically reducing oxidative stress.

Isoquinoline compounds inhibit Wnt pathway signaling and DYRK1A enzyme activity to treat cancer and neurodegenerative disorders.

Novel nitrogen-containing heterocyclic compounds inhibit the c-Met kinase pathway through specific structural modifications.

Ionic intermediates prevent phase separation in hyaluronic acid and chitosan mixtures, yielding transparent gels without covalent modification.

A topical formulation of bacitracin, polymyxin B, and triamcinolone reduces hypergranulation tissue.

Heterobifunctional compounds bind to the androgen receptor and BRD4 protein using segmented moieties linked by structural bridges.

A topical pharmaceutical compound promotes hair growth by inhibiting mitochondrial pyruvate oxidation.

Formula I heterocyclic sulfones selectively target RORγ receptors, addressing unmet needs in autoimmune disease management.

Topical MEK inhibitor formulations enable percutaneous absorption directly into affected skin tissue.